VRTX
$226.71
Vertex Pharmaceutic
$8.61
3.95%
VRTX
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  $2.29
Revenue:  $1.50 Bil
Thursday
Jan 28
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, October 29, 2020

What do you expect when VRTX reports earnings?
Beat
Meet
Miss

Where is VRTX's stock price going from here?
Up
Flat
Down
Stock chart of VRTX
Analysts
Summary of analysts' recommendations for VRTX
Score
Grade
Pivots
Resistance
$236.19
$231.46
$229.08

$224.35

Support
$221.97
$217.24
$214.86
Tweet
Growth
Description
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Peers
InterCeptRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli LillyCatalent